DelSite Biotech to Present Paper on Inactivated Nasal Powder Vaccine at Influenza Vaccines for the World 2006
Posted on: Thursday, 22 June 2006, 18:00 CDT
IRVING, Texas, June 22 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. today announced that Dr. Yawei Ni, senior scientist at DelSite Biotechnologies, Inc., Carrington's wholly-owned subsidiary, will make an oral presentation entitled "An Inactivated Influenza Nasal Powder Vaccine" on October 19, 2006 at the second International Conference on Influenza Vaccines for the World (IVW) 2006 meeting to be held in Vienna, Austria.
Dr. Ni's presentation will discuss the latest findings and development status of DelSite's proprietary inactivated influenza nasal powder vaccine, which incorporates inactivated whole virion antigens in a unique in situ gelling powder formulation. By combining the whole virion antigen and nasal delivery with a unique enabling dry powder delivery system (GelVac(TM)), this vaccine provides distinct advantages in meeting the critical needs for influenza pandemic preparedness and epidemic control. These include room temperature stability, eliminating the need for cold storage, broader protection, antigen sparing, ease of administration, and induction of both mucosal and systemic responses.
Development of the GelVac(TM) influenza vaccine is partially supported by a NIH/NIAID SBIR biodefense grant and a $6 million challenge grant.
About IVW 2006
IVW 2006 will be an international forum for world renowned experts in the field of influenza vaccines and related issues to report the latest data and trends associated with current and new influenza vaccines and their availability/delivery worldwide. The scientific programme will include keynote lectures, contributed papers, workshops, panel discussions and poster presentations emphasizing all aspects of the usage and effectiveness of influenza vaccines.
About GelVac(TM) Nasal Powder For Vaccines
DelSite's GelVac(TM) flu vaccine is uniquely suited to meeting the challenges of a pandemic. The Phase I safety in humans for the GelVac(TM) powder was completed in 2005.
* It is stable at room temperature; the vaccine requires no refrigeration for shipping or prolonged storage, facilitating both stockpiling and rapid distribution. * The powder is easily administered and could be self-administered, if necessitated by an overwhelmed health care system. * The powder gels on contact with nasal fluid, prolonging the nasal residence time and sustaining the antigen release potentially allowing for an enhanced protection.
Nasally administered vaccines form a first-line of immune defense for the upper respiratory system, a common entry point for influenza virus, as well as prompting the body's normal systemic immune response.
About DelSite
DelSite Biotechnologies, Inc. was formed based on discoveries at Carrington Laboratories, Inc., and is a wholly-owned subsidiary of Carrington. DelSite Biotechnologies is a drug delivery and biotechnology company established to provide the pharmaceutical and biotechnology industries with novel delivery solutions for vaccines and therapeutic agents.
About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based biopharmaceutical company currently utilizing naturally-occurring complex carbohydrates to:
* manufacture and market products for mucositis, radiation dermatitis, wound and oral care; * manufacture and market the nutraceutical and cosmetic raw materials Manapol(R) and Hydrapol(TM); and, * market consumer products under various brands.
Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10-Q filed on May 5, 2006.
Carrington Laboratories, Inc.
CONTACT: Carlton E. Turner, President and CEO of CarringtonLaboratories, Inc., +1-972-518-1300
Web site: http://www.carringtonlabs.com/
Source: PRNewswire-FirstCall
Related Articles
- Needle-free, Inhalant Powder Measles Vaccine May Save Thousands of Lives
- Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate
- Sanofi Pasteur Remains on Track to Deliver 50 Million Doses of Influenza Vaccine to U.S. Market for 2006-2007 Season
- CDC Director Joins Nation's Top Health Experts to Urge Americans to Seek Influenza and Pneumococcal Vaccinations This Fall and Winter
- Iomai Chief Scientific Officer Dr. Gregory Glenn to Speak on Promising Developments in Vaccines at Today's 'Modern Vaccines, Adjuvants & Delivery Systems' Conference in London
- Vical Announces Webcast of Presentations at Analyst and Investor Day Focused on Avian Influenza and Cytomegalovirus Vaccine Programs
- CytoGenix Announces Results of Influenza synDNA(TM) Vaccine Trial
- Chiron Initiates U.S. Phase I/II Study of Influenza Cell Culture Vaccine
- YM BioSciences to Present Results of Norelin(TM) Study at Cancer Vaccines/Adjuvants/Delivery 2005 Congress in Lisbon
 |
 |
User Comments (0)
RSS Feeds